Humana (HUM) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald restated their hold rating on shares of Humana (NYSE:HUM) in a research note published on Tuesday morning. The firm currently has a $230.00 target price on the insurance provider’s stock. Cantor Fitzgerald also issued estimates for Humana’s FY2018 earnings at $12.03 EPS.

Several other equities research analysts have also recently weighed in on the company. BMO Capital Markets increased their target price on Humana from $290.00 to $300.00 and gave the company an outperform rating in a report on Friday, November 10th. ValuEngine upgraded Humana from a hold rating to a buy rating in a report on Friday, September 1st. Royal Bank Of Canada restated a sector perform rating and set a $242.00 target price (down from $245.00) on shares of Humana in a report on Thursday, November 9th. Credit Suisse Group dropped their target price on Humana from $256.00 to $246.00 and set a neutral rating for the company in a report on Friday, November 10th. Finally, Zacks Investment Research cut Humana from a strong-buy rating to a hold rating in a report on Tuesday, October 17th. Twelve analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Humana presently has a consensus rating of Hold and an average price target of $255.80.

Humana (NYSE:HUM) traded up $2.59 on Tuesday, hitting $256.49. The stock had a trading volume of 967,619 shares, compared to its average volume of 1,372,488. Humana has a 1 year low of $186.25 and a 1 year high of $264.56. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61. The stock has a market cap of $36,272.18, a PE ratio of 21.66, a P/E/G ratio of 1.74 and a beta of 0.88.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. During the same period in the prior year, the business earned $3.18 EPS. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. research analysts expect that Humana will post 11.63 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is 12.59%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its position in shares of Humana by 7,848.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock worth $377,192,000 after acquiring an additional 1,547,866 shares in the last quarter. FMR LLC raised its position in shares of Humana by 29.3% in the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after acquiring an additional 1,479,210 shares in the last quarter. Koch Industries Inc. bought a new position in shares of Humana in the 2nd quarter worth approximately $404,000. TIAA CREF Investment Management LLC raised its position in shares of Humana by 39.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,358,617 shares of the insurance provider’s stock worth $326,910,000 after acquiring an additional 386,162 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Humana by 39.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,322,413 shares of the insurance provider’s stock worth $318,216,000 after acquiring an additional 376,177 shares in the last quarter. 94.19% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Humana (HUM) Rating Reiterated by Cantor Fitzgerald” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://ledgergazette.com/2017/12/09/humana-hum-rating-reiterated-by-cantor-fitzgerald.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply